English Woman's Journal - OBI Pharma Signs Collaboration and License Agreement with Novartis

OBI Pharma Signs Collaboration and License Agreement with Novartis


OBI Pharma Signs Collaboration and License Agreement with Novartis
OBI Pharma Signs Collaboration and License Agreement with Novartis

TAIPEI, TW / ACCESS Newswire / November 16, 2026 / OBI Pharma, Inc. (4174.TWO) ("OBI") announced that it has entered into a Collaboration and License agreement with Novartis Pharma AG ("Novartis") to develop next generation Antibody-Drug-Conjugates (ADCs) with novel payloads, using OBI's suite of platform technologies.

Change text size:

Under the terms of the agreement, Novartis will receive worldwide rights to OBI's related patents and know-how using its ADC platform technologies on an exclusive basis for selected, undisclosed Novartis payload classes. In parallel, under the collaboration OBI will evaluate novellinker approaches with the Novartis payloads. Novartis will further have the option to expand the agreement to include additional novel payload classes.

This agreement marks an important milestone for OBI and underscores the value of its differentiated ADC technology platform. The agreement recognizes the potential of OBI's proprietary technologies, including GlycOBI®, EndoSymeOBI®, HYPrOBI®, and GlycOBI DUO®, and supports OBI's strategy of expanding the global application of its ADC technologies through strategic agreements.

Ya-Chi Chen, Pharm.D., acting Chief Executive Officer of OBI Pharma, Inc., commented: "We are delighted to enter into this agreement with Novartis, a leading pharmaceutical company in innovative oncology drug development with extensive commercialization capabilities. This agreement recognizes the scientific and commercial potential of OBI's proprietary ADC technologies and reflects the value of our differentiated platform. By combining OBI's ADC expertise with Novartis's resources and capabilities, we aim to advance next-generation therapies that could deliver meaningful benefits to patients."

"Engaging with OBI's expertise and technologies in antibody-drug conjugation to create potential ADCs with novel payloads is an important part of our oncology ADC strategy. This collaboration supports our ambition to innovate novel therapies and potentially expand treatment options for patients," said Shiva Malek, Global Head of Oncology, Biomedical Research at Novartis.

Under the terms of the agreement, OBI will receive an upfront payment of USD 30 million and is eligible to receive development, regulatory and commercial milestone payments for a total potential deal value exceeding USD 2 billion. In addition, OBI is eligible to receive tiered royalties on net sales of the licensed products resulting from the collaboration.

About Obrion® ADC Technology

OBI has developed the proprietary Obrion® ADC Technology Platform, which integrates multiple ADC-enabling technologies to support the development of next-generation ADCs. At the core of Obrion® is GlycOBI®, a glycan-based conjugation technology with a flexible, plug-and-play design compatible with a broad range of antibodies, linkers, and payloads, while supporting different drug-to-antibody ratios (DARs).

Powered by OBI's proprietary dual-function enzymatic technology, EndoSymeOBI®, and highly hydrophilic and stable linker technology, HYPrOBI®, GlycOBI® enables the efficient and scalable production of site-specific, homogeneous ADCs under GMP conditions. GlycOBI DUO® further expands the capabilities of the Obrion® platform by enabling next-generation ADC modalities, including dual-payload ADCs.

About OBI Pharma

OBI Pharma is a clinical-stage global oncology company established in 2002 and headquartered in Taiwan, with operations in the United States and Australia. The company is focused on developing innovative cancer therapeutics and advancing proprietary antibody-drug conjugate (ADC) technologies to address unmet medical needs and provide new treatment options for patients.

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.

COMPANY CONTACT:

Jukka Muhonen
Executive Director, Business Development
OBI Pharma USA, Inc.
email: [email protected]
tel.: +1 617 821 0292

SOURCE: OBI Pharma, Inc.



View the original press release on ACCESS Newswire

E.Brwon--EWJ

Featured

2026 Nickelodeon Kids' Choice Awards: Air Time, Channels, and Streaming Guide

The 2026 Nickelodeon Kids' Choice Awards will air live from Television City in Los Angeles on Saturday, November 14, hosted by Alex Warren. The ceremony, featuring musical performances and the traditional slime segment, broadcasts from 8:00 to 9:30 p.m. ET on CBS and Nickelodeon, with additional streaming options available through DIRECTV, Paramount+, and various live TV providers.

Tiffani Thiessen Reveals Need for Hip Replacement Surgery at Age 52

Actress Tiffani Thiessen has announced that she requires hip replacement surgery at age 52 following a diagnosis of hip dysplasia and a torn labrum. Speaking on the 'Breaking Bread with Tom Papa' podcast, the former teen idol explained how her active lifestyle contributed to the condition while emphasizing her continued commitment to acting.

Kai Widdrington Withdraws from Strictly Come Dancing Due to Illness; Aljaž Škorjanec Steps In

Strictly Come Dancing professional Kai Widdrington has been confirmed to miss Saturday’s live broadcast due to illness, ending his partnership with singer Delta Goodrem for the evening. Fellow professional dancer Aljaž Škorjanec has been brought in as a replacement to perform the Argentine Tango with Goodrem. The withdrawal follows a recent injury that previously forced Goodrem to skip a prior week of the competition.

Chrisean Rock Strikes Adam22 at Wild N' Out Show Over Parenting Remarks

Chrisean Rock struck Adam22 in the back of the head during a taping of Wild N' Out at Los Angeles’ Intuit Dome on Tuesday night. The altercation occurred after Adam22 made remarks criticizing Rock’s abilities as a mother, prompting her to approach him and deliver physical blows before walking away.

Change text size: